A microRNA-mRNA regulatory network analysis platform for identifying therapeutic targets in prostate cancer disparities

Researchers identified specific microRNA and gene networks that drive aggressive prostate cancer in African American men, suggesting that targeting these molecular pathways could improve treatment and address racial disparities in prostate cancer outcomes.

Background

Prostate cancer presents a formidable global health challenge, with significant racial disparities observed in its incidence, aggressiveness, and mortality rates. A critical need exists to address these profound inequalities, as African American men disproportionately experience higher rates of diagnosis, more advanced disease at presentation, and poorer outcomes compared to men of European descent. Understanding the fundamental biological and molecular underpinnings driving these disparities is paramount for developing effective and equitable strategies to combat this disease.

Despite advancements in cancer research and treatment, current diagnostic and therapeutic approaches for prostate cancer often fail to adequately account for the distinct biological and molecular differences that contribute to varying disease courses across racial groups. This generalized approach can lead to a “one-size-fits-all” treatment paradigm that may not be optimally effective for all patients, particularly those in high-risk populations. Consequently, there is a critical gap in precisely identifying and targeting the unique molecular pathways and regulatory networks that drive aggressive prostate cancer in these specific demographics.

Technology

This research involves a detailed analysis of genomic data from prostate cancer specimens, comparing African American (AA) and European American (EA) populations to identify key molecular differences. It uncovered 10 differentially expressed microRNAs (miRNAs) and 58 regulated signaling pathways, emphasizing the ErbB-PI3K-AKT-mTOR-HIF-VEGF axis. Specifically, reduced levels of certain miRNAs in AA prostate cancer correlated with increased expression of oncogenes such as IGFBP2, MTOR, and HIF1A in the mTOR pathway. Five significant reciprocal miRNA-mRNA pairs were experimentally validated, showing that modulating these miRNA levels can alter cellular proliferation and improve sensitivity to docetaxel.

What differentiates this technological approach is its explicit focus on elucidating the molecular mechanisms underlying the higher incidence and mortality rates of prostate cancer in African American men. By identifying specific miRNA-mRNA regulatory networks and potential therapeutic targets unique to AA prostate cancer, this work provides a crucial foundation for developing precision medicine strategies. This tailored understanding allows for more targeted interventions, potentially leading to improved treatment outcomes for AA patients by addressing the aggressive nature of the disease and enhancing the efficacy of existing chemotherapies.

Benefits

  • Provides mechanistic insights into prostate cancer disparities between African American and European American men through miRNA-mRNA regulatory network analysis.
  • Identifies key dysregulated signaling pathways (ErbB-PI3K-AKT-mTOR-HIF-VEGF axis) driving aggressive prostate cancer in African American patients.
  • Enables targeted therapeutic strategies by modulating specific tumor-suppressive and oncogenic miRNAs to inhibit cancer cell proliferation.
  • Enhances sensitivity of prostate cancer cells, especially African American-derived, to docetaxel chemotherapy, improving treatment efficacy.
  • Offers potential biomarkers for risk stratification and personalized medicine approaches tailored to high-risk African American prostate cancer patients.
  • Validated across patient tissues and multiple prostate cancer cell lines, supporting translational and clinical relevance.
  • Supports development of precision medicine interventions aimed at reducing prostate cancer mortality disparities.

Applications

  • Personalized prostate cancer therapeutics
  • miRNA-based diagnostic biomarker panels
  • Drug sensitivity prediction tools
  • Targeted health disparity interventions

Additional info

This study details specific miRNA-mRNA regulatory networks and dysregulated ErbB-PI3K-AKT-mTOR-HIF-VEGF signaling underlying prostate cancer disparities in African American men. It reveals reduced tumor-suppressive miRNAs correlating with increased oncogenes. Modulating these networks inhibits cell proliferation and enhances docetaxel sensitivity, offering targeted therapeutic approaches for this population.